Yun Tan1, Jin-Xiu Li2, Xu-Dong Xiang2, Jian-Lei Lü2. 1. Department of Intensive Care Unit, The Second Xiangya Hospital, Central South University Changsha 410011, China ; Wuhan Third Hospital Wuhan 430060, China. 2. Department of Intensive Care Unit, The Second Xiangya Hospital, Central South University Changsha 410011, China.
Abstract
OBJECTIVE: To investigate the expression differences in maturation and cytokine production of dendritic cells (DCs) from sepsis patients and the effect of oxidized phospholipid 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (OXPAPC) on DCs phenotypes. METHODS: Peripheral blood mononuclear cells from 50 sepsis patients and 50 controls were cultured in the presence of GM-CSF, IL-4 and TNF-α to induce DCs maturation. DCs from sepsis patients were also treated with three different concentrations of OXPAPC. Cells were characterized with optical and electron microscopy, FACS analysis for CD1α, HLA-DR and CD86 on cell surface and ELISA analysis of IL-12p70 in the supernatant. RESULTS: DCs from sepsis patients had smaller cell bodies and nucleus and had almost no surface projection. DCs had similar CD1α expression in sepsis patients (86.37 ± 17.24) and controls (88.58 ± 10.05). HLA-DR expression was dramatically reduced in sepsis patients (2.74 ± 5.15) compared to controls (198.35 ± 12.04). Similarly, CD86 expression was also drastically lower in sepsis patients (14.72 ± 4.83) than controls (154.56 ± 11.56). Furthermore, OXPAPC treatment of DCs from sepsis patients increased cell surface projection, HLA-DR and CD86 surface expression and IL-12p70 secretion in a dose-dependent manner. With 40 μg/ml of OXPAPC, DCs of sepsis patients have similar phenotypes observed in healthy controls. CONCLUSION: DCs from sepsis patients are defective in maturation and cytokine secretion and these defects can be corrected by OXPAPC treatment.
OBJECTIVE: To investigate the expression differences in maturation and cytokine production of dendritic cells (DCs) from sepsispatients and the effect of oxidized phospholipid 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (OXPAPC) on DCs phenotypes. METHODS: Peripheral blood mononuclear cells from 50 sepsispatients and 50 controls were cultured in the presence of GM-CSF, IL-4 and TNF-α to induce DCs maturation. DCs from sepsispatients were also treated with three different concentrations of OXPAPC. Cells were characterized with optical and electron microscopy, FACS analysis for CD1α, HLA-DR and CD86 on cell surface and ELISA analysis of IL-12p70 in the supernatant. RESULTS: DCs from sepsispatients had smaller cell bodies and nucleus and had almost no surface projection. DCs had similar CD1α expression in sepsispatients (86.37 ± 17.24) and controls (88.58 ± 10.05). HLA-DR expression was dramatically reduced in sepsispatients (2.74 ± 5.15) compared to controls (198.35 ± 12.04). Similarly, CD86 expression was also drastically lower in sepsispatients (14.72 ± 4.83) than controls (154.56 ± 11.56). Furthermore, OXPAPC treatment of DCs from sepsispatients increased cell surface projection, HLA-DR and CD86 surface expression and IL-12p70 secretion in a dose-dependent manner. With 40 μg/ml of OXPAPC, DCs of sepsispatients have similar phenotypes observed in healthy controls. CONCLUSION: DCs from sepsispatients are defective in maturation and cytokine secretion and these defects can be corrected by OXPAPC treatment.
Authors: M Wysocka; S Robertson; H Riemann; J Caamano; C Hunter; A Mackiewicz; L J Montaner; G Trinchieri; C L Karp Journal: J Immunol Date: 2001-06-15 Impact factor: 5.422
Authors: Klaus Tschaikowsky; Monika Hedwig-Geissing; Albert Schiele; Frank Bremer; Michael Schywalsky; Jürgen Schüttler Journal: Crit Care Med Date: 2002-05 Impact factor: 7.598
Authors: Valery N Bochkov; Olga V Oskolkova; Konstantin G Birukov; Anna-Liisa Levonen; Christoph J Binder; Johannes Stöckl Journal: Antioxid Redox Signal Date: 2010-04-15 Impact factor: 8.401